Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
about
A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancerThe Role of Hypofractionated Radiation Therapy with Photons, Protons, and Heavy Ions for Treating Extracranial LesionsEmergence of stereotactic body radiation therapy and its impact on current and future clinical practiceExploring the role of cancer stem cells in radioresistanceNormal tissue toxicity after small field hypofractionated stereotactic body radiation.Curative stereotactic robotic radiotherapy treatment for extracranial, extrapulmonary, extrahepatic, and extraspinal tumors: technique, early results, and toxicity.Stereotactic body radiotherapy for organ-confined prostate cancer.Phase I/II trial of definitive carbon ion radiotherapy for prostate cancer: evaluation of shortening of treatment period to 3 weeksStereotactic radiotherapy of the prostate: fractionation and utilization in the United States.SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines.Dosimetry analyses comparing high-dose-rate brachytherapy, administered as monotherapy for localized prostate cancer, with stereotactic body radiation therapy simulated using CyberKnife.A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum FollStereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early resultsPhase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancerLong-term results of a study using individualized planning target volumes for hypofractionated intensity-modulated radiotherapy boost for prostate cancer.Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma.Radiation treatment for patients with intermediate-risk prostate cancer.Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer.Stereotactic Body Radiotherapy for Clinically Localized Prostate Cancer: Toxicity and Biochemical Disease-Free Outcomes from a Multi-Institutional Patient Registry.Hypofractionated external-beam radiotherapy for prostate cancer.Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.Intermediate-risk prostate cancer patients treated with androgen deprivation therapy and a hypofractionated radiation regimen with or without image guided radiotherapy.CyberKnife robotic radiosurgery system for tumor treatment.Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction.SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.Is there a role for advanced radiation therapy technologies in the treatment of pancreatic adenocarcinoma?Local coverage determination policy and the use of stereotactic body radiation therapy for prostate cancer.Technology Insight: image-guided robotic radiosurgery--a new approach for noninvasive ablation of spinal lesions.Systematic review of hypofractionated radiation therapy for prostate cancer.Stereotactic body radiation therapy for nonpulmonary primary tumors.Proton radiation for localized prostate cancer.Long-term toxicity following 3D conformal radiation therapy for prostate cancer from the RTOG 9406 phase I/II dose escalation study.Strategies for optimizing the response of cancer and normal tissues to radiation.Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials.Novel treatment methods for localized prostate cancer: hypofractionated robotic radiation therapy and adjuvant chemotherapy.Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer.Stereotactic body radiation therapy: a novel treatment modality.Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.Technological advances in radiation therapy for prostate cancer.Emerging technologies in prostate cancer radiation therapy: improving the therapeutic window.
P2860
Q26738278-091BB2FF-0A12-4655-AAA0-6F8BF7A08E0EQ26770254-1AC9EAE1-F6F4-4D57-9F3D-E750F41C9D43Q27015651-B3C82A1C-BBA5-4126-B80F-27BE4F360B31Q28282037-D7E1B62C-6B2F-4BB8-9A7B-0D3959F54F06Q30484881-4363B550-E3B5-405D-8797-60EDDFC256D0Q33305385-3CAA0301-030D-4D12-9310-82D4D53ED908Q33528163-15C681FB-908A-43BE-A758-267F614DC227Q33613649-1AE527BA-F3C1-4D06-B8FB-49906D76820AQ33919686-27ED7234-4961-438A-A460-34761DE398C6Q34487782-0E3D664E-9C1B-4B50-82B4-A4E64E046E8CQ34500918-7EB53819-9AD3-4681-B50F-5C69EACBA81FQ34510485-551E2D16-6A9D-45CC-833F-7A4F5D7F2F1DQ34660610-BCC75D2A-D66B-497C-AD2B-3EDBCCA58104Q35111775-A515E2EC-1859-4D74-A988-C41A83081B96Q35530488-0DF44B61-5C1F-4BB3-A921-79114D116790Q35649108-F449FBF2-E6C4-45CD-8229-AB6AA94205E8Q35992830-54542B63-E1CD-4210-B3E1-6FC0F25BC11CQ36174829-C8C38A02-BA6E-4403-92A9-06394AA58969Q36426682-27F2EADF-1BCF-4BB3-8B46-9CF40968FF11Q36711751-9369EB93-E85E-4127-AE2C-0736BE82540BQ36722591-6763D980-30F7-49D1-8A23-BE595F4E81D5Q36953209-C8E96256-6B59-43FB-AB75-97EECFCE130EQ37004652-9056A77B-9BFC-4097-8DBE-A833311BDB38Q37016012-DA6E670A-C3C5-4DE3-BABE-854762B2E788Q37034249-8DCA93F5-0300-4767-A105-ED27199CD273Q37137013-E800A461-38F4-4280-A246-E0A976F82525Q37143037-1D52C7EE-3ECD-4206-86D7-2F0FCD72E9B2Q37163005-82B9C4C6-ABBC-4572-835A-B4B07BACDA3AQ37324126-40341FCB-0BDA-4B23-9C3B-07BFD625DA9AQ37338255-5AC6C250-FFDF-4AE0-A85F-6FCE9BD3F2FCQ37478108-8E1889AC-7781-4255-BF73-20CD5EDB7926Q37480893-D21D729B-098E-4703-B138-D11306483BB3Q37531724-D1923F08-F7E4-486D-89E7-29FD330721CCQ37539431-D0C7041B-922F-46AA-9D18-0F58A372005AQ37546045-EDEAEC55-D6C3-4607-9CB9-37B5B0FCCB50Q37586877-B4CF0D9C-1B89-4AC4-8631-B855C85DEBC5Q37649474-24597B36-04DD-4DA3-A495-034FE1E9CCC6Q37725623-9B12182E-90DF-4C28-8EB4-8C1FB0E296F0Q37738793-1D8D677F-0A6F-415D-903B-9ABDBCC972D9Q37791392-7EA0E614-E6A8-43EE-A256-22F48CF266B2
P2860
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Stereotactic hypofractionated ...... first clinical trial results.
@en
Stereotactic hypofractionated ...... first clinical trial results.
@nl
type
label
Stereotactic hypofractionated ...... first clinical trial results.
@en
Stereotactic hypofractionated ...... first clinical trial results.
@nl
prefLabel
Stereotactic hypofractionated ...... first clinical trial results.
@en
Stereotactic hypofractionated ...... first clinical trial results.
@nl
P2093
P1476
Stereotactic hypofractionated ...... first clinical trial results.
@en
P2093
Berit L Madsen
Huong T Pham
Jack F Fowler
John Corman
Laura Esagui
R Alex Hsi
P304
P356
10.1016/J.IJROBP.2006.10.050
P407
P577
2007-03-01T00:00:00Z